Browse > Article

Application of chitosan resin formulae as a sustained-releasing form adjuvant  

Kim, Sang-Uk (Jeollanamdo Institute of Livestock & Veterinary Science)
Kang, Mun-Il (College of Veterinary Medicine, Chonnam National University)
Lee, Jae-Il (College of Veterinary Medicine, Chonnam National University)
Kim, Tae-Jung (College of Veterinary Medicine, Chonnam National University)
Publication Information
Korean Journal of Veterinary Service / v.33, no.2, 2010 , pp. 173-176 More about this Journal
Abstract
Here, we report the suitability of using a resin-type chitosan formulae as a sustained-releasing form adjuvant in comparison with commercially well-known Freund's adjuvants. To induce the immunological responses, N-terminal region of Pasteurella multocida toxin was used as an antigen, which was found to be protective immunogen against P. multocida infection. Mice immunized with chitosan resin formulae showed statistically significant antibody induction (P<0.001) as much as that of Freund’s adjuvants. As a result, the resin-type sustained-releasing form chitosan formulae is thought to be a good candidate for a new type adjuvant.
Keywords
Chitosan; Adjuvant; Pasteurella multocida toxin (PMT); Sustained-release;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Projean D, Lessard E, Ducharme MP, Ducharme J. 2007. Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: Consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. Xenobiotica 37: 870-883.   DOI   ScienceOn
2 Bacon A, Makin J, Sizer PJ, Jabbal-Gill, Hinchcliffe M, Illum L, Chatfield S, Roberts M. 2000. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 68: 5764-5770.   DOI   ScienceOn
3 McNeela EA, Jabbal-Gill I, IlIum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH. 2004. Intranasal immunization with genetically detoxified diphtheria toxin induces T eel! responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22: 909-914.   DOI   ScienceOn
4 Mi FL, Shyu SS, Chen CT, Schoung JY. 1999. Porous chitosan microsphere for controlling the antigen release of Newcastle disease vaccine: preparation of antigenadsorbed microsphere and in vitro release. Biomaterials 20: 1603-1612.   DOI   ScienceOn
5 Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41.   DOI   ScienceOn
6 van def Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. 2003. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21: 1400-1408.   DOI   ScienceOn
7 Seo JY, Pyo HJ, Lee SM, Lee JI, Kim TJ. 2009. Expression of 4 truncated fragments of Pasteurella multocida toxin and their immunogenicity. Can J Vet Res 73: 184-189.
8 Kim TJ, Kim KH, Lee JI. 2007. Stimulation of mucosal and systemic antibody responses against recombinant transferrin- binding protein B of Actinobacillus pleuropneumoniae. J Vet Med Sci 69: 535-539.   DOI   ScienceOn
9 lIlum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15: 1326-1331.   DOI   ScienceOn
10 IlIum L, Farraj NF, Davis SS. 1994. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11: 1186-1189.   DOI   ScienceOn